ES2395839T3 - Miembro de unión para el receptor GM-CSF - Google Patents

Miembro de unión para el receptor GM-CSF Download PDF

Info

Publication number
ES2395839T3
ES2395839T3 ES07712963T ES07712963T ES2395839T3 ES 2395839 T3 ES2395839 T3 ES 2395839T3 ES 07712963 T ES07712963 T ES 07712963T ES 07712963 T ES07712963 T ES 07712963T ES 2395839 T3 ES2395839 T3 ES 2395839T3
Authority
ES
Spain
Prior art keywords
sec
ident
antibody
binding member
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07712963T
Other languages
English (en)
Spanish (es)
Inventor
Emma Suzanne Cohen
Ralph Raymond Minter
Paula Rosamund Harrison
Matthew Alexander Sleeman
Andrew Donald Nash
Louis Jerry Fabri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL IP Investments Pty Ltd
MedImmune Ltd
Original Assignee
Zenyth Operations Pty Ltd
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyth Operations Pty Ltd, MedImmune Ltd filed Critical Zenyth Operations Pty Ltd
Application granted granted Critical
Publication of ES2395839T3 publication Critical patent/ES2395839T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
ES07712963T 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF Active ES2395839T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
US786569P 2006-03-27
PCT/GB2007/001108 WO2007110631A1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor

Publications (1)

Publication Number Publication Date
ES2395839T3 true ES2395839T3 (es) 2013-02-15

Family

ID=38293698

Family Applications (3)

Application Number Title Priority Date Filing Date
ES07712963T Active ES2395839T3 (es) 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF
ES11167912T Active ES2424467T3 (es) 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF
ES11167923T Active ES2424468T3 (es) 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES11167912T Active ES2424467T3 (es) 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF
ES11167923T Active ES2424468T3 (es) 2006-03-27 2007-03-27 Miembro de unión para el receptor GM-CSF

Country Status (15)

Country Link
US (8) US8506960B2 (enExample)
EP (3) EP1999152B1 (enExample)
JP (2) JP5335662B2 (enExample)
KR (2) KR101451546B1 (enExample)
CN (3) CN103641916A (enExample)
BR (1) BRPI0709259B1 (enExample)
CA (1) CA2647449C (enExample)
DK (3) DK1999152T3 (enExample)
ES (3) ES2395839T3 (enExample)
MX (2) MX348827B (enExample)
PL (3) PL2423230T3 (enExample)
PT (3) PT1999152E (enExample)
RU (2) RU2495050C2 (enExample)
SI (3) SI2423229T1 (enExample)
WO (1) WO2007110631A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2527590B2 (ja) 1988-02-17 1996-08-28 三洋電機株式会社 空冷式吸収冷凍機
EP1999152B1 (en) * 2006-03-27 2012-09-19 Medimmune Limited Binding member for gm-csf receptor
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US8075885B2 (en) 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
KR101898982B1 (ko) * 2008-12-22 2018-09-14 더 유니버시티 오브 멜버른 골관절염 치료
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
WO2011028697A2 (en) * 2009-09-03 2011-03-10 The Regents Of The University Of Colorado, A Body Corporate Uses of cd 116 expression level
ES2660776T3 (es) 2011-10-10 2018-03-26 Medimmune Limited Tratamiento para la artritis reumatoide
CA2856329A1 (en) * 2011-11-17 2013-05-23 Nencki Institute Of Experimental Biology Compositions and methods for treating glioma
EP2602264A1 (en) * 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
CA3108192A1 (en) * 2012-12-14 2014-06-19 Biontech Rna Pharmaceuticals Gmbh Novel mhc-independent tumor-associated antigens
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
AU2015257798C1 (en) 2014-05-07 2020-10-22 Takeda Pharmaceutical Company Limited Liquid formulation comprising GM-CSF neutralizing compound
WO2015177097A1 (en) 2014-05-19 2015-11-26 Medimmune Limited Treatment for rheumatoid arthritis
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11613580B2 (en) 2016-05-24 2023-03-28 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
MX2019010282A (es) 2017-03-01 2020-01-09 Medimmune Ltd Formulacion de anticuerpos monoclonales.
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
CA3117380A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
BR112021009709A2 (pt) * 2018-11-27 2021-10-19 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTICORPOS ANTI-GM-CSFRa ISOLADOS, MOLÉCULA DE ÁCIDO NUCLEICO ISOLADA, VETOR, CÉLULAHOSPEDEIRA ISOLADA, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA E MÉTODO DE PRODUÇÃO DE ANTICORPO ANTI-GM-CSFRa ISOLADO
AU2020287327A1 (en) 2019-06-03 2022-03-10 Kiniksa Pharmaceuticals, Gmbh Treatment of cancers with GM-CSF antagonists
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
EP4232162A1 (en) * 2020-10-26 2023-08-30 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
EP4263597A2 (en) 2020-12-18 2023-10-25 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
CA2064814C (en) * 1989-08-11 2004-06-08 Nicos Anthony Nicola Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
KR101143035B1 (ko) * 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
RU2366664C2 (ru) * 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
EP1999152B1 (en) * 2006-03-27 2012-09-19 Medimmune Limited Binding member for gm-csf receptor
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
US8506960B2 (en) 2013-08-13
EP1999152B1 (en) 2012-09-19
PT2423230E (pt) 2013-08-26
RU2495050C2 (ru) 2013-10-10
PT2423229E (pt) 2013-08-22
AU2007231128A1 (en) 2007-10-04
EP2423229B1 (en) 2013-05-08
CN103641915A (zh) 2014-03-19
CA2647449A1 (en) 2007-10-04
WO2007110631A1 (en) 2007-10-04
DK2423230T3 (da) 2013-08-05
PT1999152E (pt) 2013-01-07
SI2423230T1 (sl) 2013-09-30
US20150376285A1 (en) 2015-12-31
DK2423229T3 (da) 2013-08-05
PL1999152T3 (pl) 2013-05-31
DK1999152T3 (da) 2013-01-14
US20210147559A1 (en) 2021-05-20
ES2424468T3 (es) 2013-10-02
CN103641916A (zh) 2014-03-19
KR20080113262A (ko) 2008-12-29
HK1166988A1 (en) 2012-11-16
JP5335662B2 (ja) 2013-11-06
ES2424467T3 (es) 2013-10-02
KR101451546B1 (ko) 2014-10-16
US20140079708A1 (en) 2014-03-20
JP2013121350A (ja) 2013-06-20
CN103641915B (zh) 2017-04-12
US20190040145A1 (en) 2019-02-07
SI2423229T1 (sl) 2013-09-30
US9085628B2 (en) 2015-07-21
US20190309077A1 (en) 2019-10-10
EP1999152A1 (en) 2008-12-10
BRPI0709259A2 (pt) 2011-06-28
KR101481844B1 (ko) 2015-01-13
PL2423230T3 (pl) 2013-10-31
HK1166989A1 (en) 2012-11-16
BRPI0709259B1 (pt) 2022-05-31
MX348827B (es) 2017-06-30
JP2009533020A (ja) 2009-09-17
EP2423230B1 (en) 2013-05-08
RU2008137763A (ru) 2010-05-10
CN101443360A (zh) 2009-05-27
US8263075B2 (en) 2012-09-11
KR20130140186A (ko) 2013-12-23
EP2423229A1 (en) 2012-02-29
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
EP2423230A1 (en) 2012-02-29
CA2647449C (en) 2017-05-16
RU2012157042A (ru) 2014-07-10
US20120141464A1 (en) 2012-06-07
JP5665894B2 (ja) 2015-02-04
US20090130093A1 (en) 2009-05-21
RU2639546C2 (ru) 2017-12-21
CN101443360B (zh) 2013-11-27
US20240124596A1 (en) 2024-04-18
SI1999152T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
ES2395839T3 (es) Miembro de unión para el receptor GM-CSF
AU2013200962B2 (en) Binding member for GM-CSF receptor
AU2007231128B2 (en) Binding member for GM-CSF receptor
HK1195323A (en) Binding member for gm-csf receptor
HK1166988B (en) Binding member for gm-csf receptor
HK1166989B (en) Binding member for gm-csf receptor
HK1195324A (en) Binding member for gm-csf receptor
HK1195324B (en) Binding member for gm-csf receptor